Vazoket tablets 600mg, No. 30

• Varicose veins;

• chronic lymphovenous insufficiency of the lower extremities;

• exacerbation of hemorrhoids;

• microcirculation disorders.

With varicose veins of the lower extremities and in the initial stage of chronic lymphovenous insufficiency (heaviness in the legs), 1 tablet is prescribed per day in the morning before breakfast for 2 months, with severe forms of chronic lymphovenous insufficiency (edema, pain, convulsions, etc.) - treatment is continued for 3-4 months, in the presence of trophic changes and ulcers, treatment is extended to 6 months or more. The course is repeated in 2-3 months.

In case of exacerbation of hemorrhoids, the drug is prescribed 2-3 tablets per day with meals for 7 days, then, if necessary, you can continue 1 tablet 1 time per day for 1-2 months.

In the treatment of chronic lymphovenous insufficiency during the II and III trimester of pregnancy, 1 tablet is prescribed 1 time per day and canceled 2-3 weeks before delivery.

If you miss one or more doses, continue using the drug at your usual dosage.

Active ingredient: diosmin 600 mg.

Excipients: povidone, microcrystalline cellulose, corn starch, magnesium stearate.

• age under 18;

• hypersensitivity to the components of the drug.

Trade name of the drug : VasoketЃ

International non-proprietary name : diosmin

Dosage form : tablets

Composition

Active ingredient: diosmin 600 mg.

Excipients: povidone, microcrystalline cellulose, corn starch, magnesium stearate.

Description

Oblong tablets from grayish-yellow to light yellow in color with a fracture line on both sides.

Pharmacotherapeutic group: venotonic and venoprotective agent.

ATX code : [C05CA03]

Pharmacological properties

Pharmacodynamics

Diosmin has a venotonic effect (reduces the elasticity of veins, increases the tone of the veins (dose-dependent effect), reduces venous congestion), improves lymphatic drainage (increases the tone and frequency of contraction of lymphatic capillaries, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases capillary resistance (dose-dependent effect), reduces their permeability), reduces the adhesion of leukocytes to the venous wall and their migration to paravenous tissues, improves oxygen diffusion and perfusion in the skin tissue, has an anti-inflammatory effect. Strengthens the vasoconstrictor effect of adrenaline, norepinephrine, serotonin, blocks the production of free radicals, the synthesis of prostaglandins and thromboxane. ...

Pharmacokinetics

After oral administration, the drug is rapidly absorbed from the gastrointestinal tract and is determined in blood plasma after 2 hours. The maximum concentration in blood plasma is reached 5 hours after ingestion. It is evenly distributed and accumulates in all layers of the wall of the vena cava and saphenous veins of the lower extremities, to a lesser extent in the kidneys, liver, lungs and other organs. Selective accumulation of diosmin and / or its metabolites in venous vessels reaches a maximum by 9 hours after administration and lasts for 96 hours. Diosmin is excreted by the kidneys 79%, intestines - 11%, with bile - 2.4%.

Indications for use

Varicose veins of the lower extremities, chronic lymphovenous insufficiency of the lower extremities; exacerbation of hemorrhoids; microcirculation disorders.

Contraindications

Hypersensitivity to the components of the drug, children (under 18 years of age).

Application during pregnancy and during breastfeeding

Until now, in clinical practice, there have been no reports of any side effects when using the drug in pregnant women . In experimental studies, there was no teratogenic effect on the fetus. During breastfeeding, it is not recommended to take the drug, since there is no data on the penetration of the drug into breast milk.

Method of administration and dosage

With varicose veins of the lower extremities and in the initial stage of chronic lymphovenous insufficiency (heaviness in the legs), 1 tablet is prescribed per day in the morning before breakfast for 2 months, with severe forms of chronic lymphovenous insufficiency (edema, pain, convulsions, etc.) - treatment is continued for 3-4 months, in the presence of trophic changes and ulcers, treatment is extended to 6 months or more. The course is repeated in 2-3 months.

In case of exacerbation of hemorrhoids, the drug is prescribed 2-3 tablets per day with meals for 7 days, then, if necessary, you can continue 1 tablet 1 time per day for 1-2 months.

In the treatment of chronic lymphovenous insufficiency during the II and III trimester of pregnancy, 1 tablet is prescribed 1 time per day and canceled 2-3 weeks before delivery.

If you miss one or more doses, continue using the drug at your usual dosage.

Side effect

In rare cases, from the gastrointestinal tract - dyspeptic disorders, from the central nervous system - headache.

Overdose

Overdose symptoms are not described.

Interaction with other medicinal products

Clinically significant effects of interaction with other drugs have not been described.

special instructions

Treatment of exacerbation of hemorrhoids is carried out in combination with other drugs, in the absence of a quick clinical effect, it is necessary to conduct an additional examination and adjust the therapy.

There is evidence of the possible effectiveness of the drug in the treatment of placental insufficiency, for the prevention of bleeding that occurs when using intrauterine devices and during phlebectomy.

Release form

600 mg tablets.

15 tablets in a blister made of polyvinyl chloride film and aluminum foil.

1 or 2 blisters together with instructions for use in a cardboard box.

Storage conditions

Store at a temperature not exceeding 30 ? C.

Keep out of the reach of children.

Shelf life

3 years

Do not use after the expiration date printed on the package.

Vacation conditions

On prescription

Holder (owner) of the registration certificate:

Stragen Pharma SA, 3 Chemin du Pre Fleury, 1228 Plan-les-Ots, Switzerland

Manufacturer of finished dosage form, packer (primary packaging), secondary (consumer) packaging, issuing quality control:

Fiteo Laboratuar, 11 rue de Montbazon, 37260 Mont, France

Representative of the company of the holder (owner) of the registration certificate:

SEM Pharmaceuticals Limited, 119311, Moscow, Prospekt Vernadsky, 6, room XCI, room 60, office 634

You can inform the manufacturer of all adverse reactions to drugs:

• by filling out a special form on the website www.drugsafety.ru

• by sending information to e-mail: [email protected]

• by calling the free round-the-clock phone: 8-800-777-8-604